MA39912A - Dérivés de 2-aryl-4-hydroxy-1,3-thiazole comme antagonistes du trpm8, et leur utilisation dans le traitement de la neuralgie, de la douleur, de la bpco et de l'asthme. - Google Patents
Dérivés de 2-aryl-4-hydroxy-1,3-thiazole comme antagonistes du trpm8, et leur utilisation dans le traitement de la neuralgie, de la douleur, de la bpco et de l'asthme.Info
- Publication number
- MA39912A MA39912A MA039912A MA39912A MA39912A MA 39912 A MA39912 A MA 39912A MA 039912 A MA039912 A MA 039912A MA 39912 A MA39912 A MA 39912A MA 39912 A MA39912 A MA 39912A
- Authority
- MA
- Morocco
- Prior art keywords
- neuralgia
- copd
- asthma
- pain
- aryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/36—One oxygen atom
- C07D263/42—One oxygen atom attached in position 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14173502 | 2014-06-23 | ||
| EP15730801.6A EP3157918B1 (fr) | 2014-06-23 | 2015-06-23 | Dérivés de 2-aryl-4-hydroxy-1,3-thiazole comme antagonistes du trpm8, et leur utilisation dans le traitement de la neuralgie, de la douleur, de la bpco et de l'asthme. |
| PCT/EP2015/064146 WO2015197640A1 (fr) | 2014-06-23 | 2015-06-23 | Dérivés du 2-aryl-4-hydroxy-1,3-thiazole utilisables comme inhibiteurs du trpm8 dans le traitement de la névralgie, de la douleur, de la broncho-pneumopathie chronique obstructive et de l'asthme |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA39912A true MA39912A (fr) | 2017-04-26 |
| MA39912B1 MA39912B1 (fr) | 2019-05-31 |
Family
ID=50979632
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA39912A MA39912B1 (fr) | 2014-06-23 | 2015-06-23 | Dérivés de 2-aryl-4-hydroxy-1,3-thiazole comme antagonistes du trpm8, et leur utilisation dans le traitement de la neuralgie, de la douleur, de la bpco et de l'asthme. |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US10196368B2 (fr) |
| EP (1) | EP3157918B1 (fr) |
| JP (1) | JP6557332B2 (fr) |
| KR (1) | KR102493005B1 (fr) |
| CN (1) | CN106660975B (fr) |
| AU (1) | AU2015279272B2 (fr) |
| CY (1) | CY1121624T1 (fr) |
| DK (1) | DK3157918T3 (fr) |
| EA (1) | EA034525B1 (fr) |
| ES (1) | ES2724111T3 (fr) |
| HR (1) | HRP20190819T1 (fr) |
| HU (1) | HUE043586T2 (fr) |
| LT (1) | LT3157918T (fr) |
| MA (1) | MA39912B1 (fr) |
| ME (1) | ME03399B (fr) |
| PL (1) | PL3157918T3 (fr) |
| PT (1) | PT3157918T (fr) |
| RS (1) | RS58590B1 (fr) |
| SI (1) | SI3157918T1 (fr) |
| TR (1) | TR201905319T4 (fr) |
| WO (1) | WO2015197640A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3184524A1 (fr) * | 2015-12-21 | 2017-06-28 | Dompé farmaceutici S.p.A. | Dérivés de 4-hydroxy-2-phenyl-1,3-thiazole-méthanone en tant qu'antagonistes du trpm8 |
| EP3409277A1 (fr) * | 2017-05-30 | 2018-12-05 | Dompé farmaceutici s.p.a. | Inhibiteurs il-8 destinés à être utilisés dans le traitement et/ou la prévention d'infections secondaires bactériennes |
| EP3782702A1 (fr) * | 2019-08-21 | 2021-02-24 | AC BioScience SA | Compositions et leur utilisation pour le traitement de maladies infectieuses et du cancer |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69122084T2 (de) | 1990-11-30 | 1997-04-03 | Teijin Ltd | 2-arylthiazolderivat sowie dieses enthaltendes arzneimittel |
| CA2583015A1 (fr) | 2004-10-13 | 2006-04-20 | Bayer Healthcare Ag | Derives de 4-benzyloxy-phenylmethylamide substitues utilises comme antagonistes de recepteur 1 au froid active par menthol (cmr-1) pour traiter des troubles urologiques |
| WO2007017093A1 (fr) | 2005-08-04 | 2007-02-15 | Bayer Healthcare Ag | Derives amides d'acide 2-benzyloxy-benzoique substitue |
| WO2007017092A1 (fr) | 2005-08-04 | 2007-02-15 | Bayer Healthcare Ag | Derives amides d'acide 4-benzyloxy-benzoique substitue |
| WO2007017094A1 (fr) | 2005-08-04 | 2007-02-15 | Bayer Healthcare Ag | Dérivés benzyloxyphénylméthylcarbamate substitués |
| WO2007080109A1 (fr) | 2006-01-16 | 2007-07-19 | Bayer Healthcare Ag | Dérivés de benzyloxyphénylméthylurée substitués |
| US7897781B2 (en) | 2006-05-10 | 2011-03-01 | Janssen Pharmaceutica Nv | Cold menthol receptor-1 antagonists |
| JP5539868B2 (ja) | 2007-07-18 | 2014-07-02 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｔｒｐｍ８モジュレーターとしてのスルホンアミド類 |
| WO2010103381A1 (fr) | 2009-03-13 | 2010-09-16 | Glenmark Pharmaceuticals S.A. | Dérivés de pipéridine spirocycliques en tant que modulateurs de trpm8 |
| KR20140071518A (ko) | 2009-05-01 | 2014-06-12 | 라퀄리아 파마 인코포레이티드 | Ｔｒｐｍ8 길항제로서의 설파모일 벤조산 유도체 |
| EP2606888A1 (fr) | 2011-12-19 | 2013-06-26 | Dompe' S.P.A. | Antagonistes du TRPM8 |
| PT2793883T (pt) * | 2011-12-19 | 2018-07-18 | Dompe Farm Spa | Antagonistas de trpm8 |
-
2015
- 2015-06-23 LT LTEP15730801.6T patent/LT3157918T/lt unknown
- 2015-06-23 RS RS20190461A patent/RS58590B1/sr unknown
- 2015-06-23 TR TR2019/05319T patent/TR201905319T4/tr unknown
- 2015-06-23 ME MEP-2019-110A patent/ME03399B/fr unknown
- 2015-06-23 HU HUE15730801A patent/HUE043586T2/hu unknown
- 2015-06-23 WO PCT/EP2015/064146 patent/WO2015197640A1/fr active Application Filing
- 2015-06-23 PT PT15730801T patent/PT3157918T/pt unknown
- 2015-06-23 DK DK15730801.6T patent/DK3157918T3/da active
- 2015-06-23 CN CN201580030277.1A patent/CN106660975B/zh active Active
- 2015-06-23 EP EP15730801.6A patent/EP3157918B1/fr active Active
- 2015-06-23 SI SI201530723T patent/SI3157918T1/sl unknown
- 2015-06-23 EA EA201790072A patent/EA034525B1/ru unknown
- 2015-06-23 MA MA39912A patent/MA39912B1/fr unknown
- 2015-06-23 ES ES15730801T patent/ES2724111T3/es active Active
- 2015-06-23 US US15/321,364 patent/US10196368B2/en active Active
- 2015-06-23 KR KR1020167035368A patent/KR102493005B1/ko active IP Right Grant
- 2015-06-23 JP JP2017519806A patent/JP6557332B2/ja active Active
- 2015-06-23 PL PL15730801T patent/PL3157918T3/pl unknown
- 2015-06-23 AU AU2015279272A patent/AU2015279272B2/en active Active
-
2018
- 2018-12-06 US US16/211,722 patent/US11046662B2/en active Active
-
2019
- 2019-05-02 HR HRP20190819TT patent/HRP20190819T1/hr unknown
- 2019-05-10 CY CY20191100508T patent/CY1121624T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP6557332B2 (ja) | 2019-08-07 |
| RS58590B1 (sr) | 2019-05-31 |
| AU2015279272B2 (en) | 2018-01-18 |
| KR102493005B1 (ko) | 2023-01-30 |
| ES2724111T3 (es) | 2019-09-06 |
| LT3157918T (lt) | 2019-05-27 |
| CY1121624T1 (el) | 2020-07-31 |
| US20170190678A1 (en) | 2017-07-06 |
| MA39912B1 (fr) | 2019-05-31 |
| PT3157918T (pt) | 2019-05-09 |
| TR201905319T4 (tr) | 2019-05-21 |
| US20190106395A1 (en) | 2019-04-11 |
| US10196368B2 (en) | 2019-02-05 |
| CN106660975B (zh) | 2019-12-31 |
| EP3157918B1 (fr) | 2019-03-27 |
| US11046662B2 (en) | 2021-06-29 |
| PL3157918T3 (pl) | 2019-08-30 |
| AU2015279272A2 (en) | 2017-01-19 |
| SI3157918T1 (sl) | 2019-05-31 |
| CN106660975A (zh) | 2017-05-10 |
| HUE043586T2 (hu) | 2019-08-28 |
| AU2015279272A1 (en) | 2017-01-12 |
| ME03399B (fr) | 2020-01-20 |
| JP2017520623A (ja) | 2017-07-27 |
| KR20170031664A (ko) | 2017-03-21 |
| EA034525B1 (ru) | 2020-02-17 |
| EA201790072A1 (ru) | 2017-11-30 |
| WO2015197640A1 (fr) | 2015-12-30 |
| EP3157918A1 (fr) | 2017-04-26 |
| HRP20190819T1 (hr) | 2019-06-28 |
| DK3157918T3 (da) | 2019-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA39960A (fr) | Composés imidazo[4,5c]quinoline-2-one et leur utilisation dans le traitement du cancer | |
| LTC3057969I2 (lt) | Kompozicijos, naudojamos gydyti sutrikimams, susijusiems su kit | |
| IL264049A (en) | Compounds, preparations and methods for treating the disease | |
| IL255509B (en) | Compounds as modulators of ccr2, pharmaceutical preparations containing them and their use in the treatment of diseases | |
| IL264156A (en) | Compounds, preparations and methods for treating the disease | |
| MA50482A (fr) | Dérivés cyclisés de sulfamoylarylamide et leur utilisation comme médicaments pour le traitement de l'hépatite b | |
| EP3518907A4 (fr) | Structures à nanofibres et procédés d'utilisation de celles-ci | |
| WO2016044189A8 (fr) | Méthodes de traitement du cancer faisant appel à un antagoniste se liant à l'axe pd-1 et à des antagonistes se liant à l'il-17 | |
| HK1253769A1 (zh) | 用於診斷和治療腎上腺腦白質營養不良的方法和組合物 | |
| EP3337465A4 (fr) | Compositions et méthodes d'utilisation en association destinées au traitement et au diagnostic de maladies auto-immunes | |
| ZA201901826B (en) | Cell suspension for use in the treatment of lower extremity peripheral artery disease | |
| DK3481846T3 (da) | 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande | |
| DK3882250T3 (da) | Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser | |
| MA44762A (fr) | Sémaglutide utilisé dans le traitement de maladies cardiovasculaires | |
| CL2014003325A1 (es) | Compuestos derivados de difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos, inhibidores de bace 1; composicion farmaceutica; y su uso en el tratamiento de enfermedades con niveles elevados de beta-amiloide, tal como la enfermedad de alzheimer | |
| PL3722291T3 (pl) | Związki indolinonowe i ich zastosowanie w leczeniu chorób zwłóknieniowych | |
| MA39912A (fr) | Dérivés de 2-aryl-4-hydroxy-1,3-thiazole comme antagonistes du trpm8, et leur utilisation dans le traitement de la neuralgie, de la douleur, de la bpco et de l'asthme. | |
| DK3389653T3 (da) | 2-iminobiotin til anvendelse i behandling af hjernecellelæsion | |
| GB201504387D0 (en) | Materials and methods for the treatment of vascular disease | |
| EP3208262A4 (fr) | Composés dérivés d'acrylate de 3-alkylamine-1h-indolyle et leur utilisation dans le traitement de maladies neurodégénératives | |
| IL290902A (en) | The compounds for the detection of beta-lactamases and the methods of their use | |
| MA42914A (fr) | Composés tricycliques et leur utilisation dans le traitement du cancer | |
| MA41090A (fr) | Antagoniste de a2a faiblement dosé pour le traitement du tdah et de la maladie de parkinson | |
| FI20136136A (fi) | Menetelmä kosmeettisten koostumusten valmistamiseksi, kosmeettiset koostumukset sekä niiden käyttö | |
| ZA201801945B (en) | Compositions and methods for the treatment of parkinson's disease |